Widespread Use of Toxic Skin Lightening Compounds: Medical and Psychosocial Aspects Barry Ladizinski, MD a , Nisha Mistry, MD b , Roopal V. Kundu, MD c, * Disorders of hyperpigmentation and skin lightening treatments have a significant impact on the dermatologic, physiologic, psychologic, economic, social, and cultural aspects of life. Skin lightening compounds or bleaching agents are chemicals used to achieve a lighter skin tone or whiten skin. These compounds are commonly used by individuals with hyperpigmentation disor- ders, such as melasma and postinflammatory hyperpigmentation (PIH), or those that desire lighter skin for cosmetic reasons. The most commonly used skin lightening products contain hydroquinone, topical corticosteroids (TCs), or mercury. Despite their apparent effectiveness, numerous cutaneous and systemic complications have been associated with these agents (Table 1), resulting in more stringent regulations regarding the preparation and distribution of skin lightening products. In addition to the medical implications and patient safety concerns, the psychosocial aspects of hyperpigmentation disorders are important to consider, particularly their impact on quality of life, to further elucidate the motivations for skin bleaching. MEDICAL USE OF TOPICAL SKIN LIGHTENING COMPOUNDS Hydroquinone The most commonly used over-the-counter (OTC) and prescription skin lightening preparation is a ubiquitous phenol compound known as hydro- quinone or 1,4-dihydroxybenzene. 1 Topical appli- cation of hydroquinone competitively inhibits melanogenesis through suppression of tyrosi- nase 2 and subsequent release of semiquinone free radicals, which are toxic to melanosomes. 3 In rat and human skin in vitro studies, hydroqui- none has been shown to penetrate the epidermis and continue into the dermis, subcutaneous tissue, and circulation. 4 Hydroquinone’s ability to lighten skin was first reported by Oettel in 1936, 5 when hydroquinone ingestion caused pigmentation changes in Disclosures: The authors have nothing to disclose; Funding sources: none. a Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, 1074 LMP, PO. Box 208030, New Haven, CT 06520-8030, USA b Department of Dermatology and Skin Science, University of British Columbia, 835 West 10th Avenue, Vancouver, BC V5Z 4E8, Canada c Department of Dermatology, Northwestern University Feinberg School of Medicine, 676 North Saint Clair Street, Suite 1600, Chicago, IL 60611, USA * Corresponding author. E-mail address: [email protected]KEYWORDS Skin lightening Skin bleaching Skin whitening Hydroquinone Exogenous ochronosis Mercury poisoning Topical corticosteroids Hyperpigmentation Dermatol Clin 29 (2011) 111–123 doi:10.1016/j.det.2010.08.010 0733-8635/11/$ e see front matter Ó 2011 Elsevier Inc. All rights reserved. derm.theclinics.com
13
Embed
Widespread Use of Toxic Skin Lightening Compounds- Medical and Psychosocial Aspects
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Widespread Use ofToxic Skin LighteningCompounds: Medicaland PsychosocialAspects
Barry Ladizinski, MDa, Nisha Mistry, MDb,Roopal V. Kundu, MDc,*
Disorders of hyperpigmentation and skinlightening treatments have a significant impacton the dermatologic, physiologic, psychologic,economic, social, and cultural aspects of life.Skin lightening compounds or bleaching agentsare chemicals used to achieve a lighter skin toneor whiten skin. These compounds are commonlyused by individuals with hyperpigmentation disor-ders, such as melasma and postinflammatoryhyperpigmentation (PIH), or those that desirelighter skin for cosmetic reasons. The mostcommonly used skin lightening products containhydroquinone, topical corticosteroids (TCs), ormercury. Despite their apparent effectiveness,numerous cutaneous and systemic complicationshave been associated with these agents (Table 1),resulting in more stringent regulations regardingthe preparation and distribution of skin lighteningproducts. In addition to the medical implicationsand patient safety concerns, the psychosocialaspects of hyperpigmentation disorders areimportant to consider, particularly their impact on
Disclosures: The authors have nothing to disclose; Fundia Department of Internal Medicine, Yale University SPO. Box 208030, New Haven, CT 06520-8030, USAb Department of Dermatology and Skin Science, UnivVancouver, BC V5Z 4E8, Canadac Department of Dermatology, Northwestern UniversityStreet, Suite 1600, Chicago, IL 60611, USA* Corresponding author.E-mail address: [email protected]
Dermatol Clin 29 (2011) 111–123doi:10.1016/j.det.2010.08.0100733-8635/11/$ e see front matter � 2011 Elsevier Inc. A
quality of life, to further elucidate the motivationsfor skin bleaching.
MEDICAL USE OF TOPICAL SKIN LIGHTENINGCOMPOUNDSHydroquinone
The most commonly used over-the-counter (OTC)and prescription skin lightening preparation isa ubiquitous phenol compound known as hydro-quinone or 1,4-dihydroxybenzene.1 Topical appli-cation of hydroquinone competitively inhibitsmelanogenesis through suppression of tyrosi-nase2 and subsequent release of semiquinonefree radicals, which are toxic to melanosomes.3
In rat and human skin in vitro studies, hydroqui-none has been shown to penetrate the epidermisand continue into the dermis, subcutaneoustissue, and circulation.4
Hydroquinone’s ability to lighten skin was firstreported by Oettel in 1936,5 when hydroquinoneingestion caused pigmentation changes in
ng sources: none.chool of Medicine, 333 Cedar Street, 1074 LMP,
ersity of British Columbia, 835 West 10th Avenue,
Feinberg School of Medicine, 676 North Saint Clair
black-haired cats, which was reversible afterhydroquinone discontinuation. Shortly after, in1941, Martin and Ansbacher6 showed that hydro-quinone ingestion induced graying of hair inmice. In the 1950s, hydroquinone was used asa sunscreen in the Southern United States, andusers reported skin lightening as a complication.7
Since 1956, hydroquinone has been available invarious OTC formulations for skin lighteningpurposes in the United States.8 In 1961, Spencer9
reported the first clinical trial evaluating hydroqui-none as a skin lightener, and since then hydroqui-none has remained the preferred treatment forvarious hyperpigmentation disorders, such asmelasma, PIH, and lentigines.
Topical Corticosteroids
TCs are subdivided according to strength (classIeVII), with class I (ie, clobetasol) being the mostpotent and class VII (ie, hydrocortisone) the leastpotent.10 The strength of TCs is determined bythe vasoconstriction assay, in which potency isassociated with the degree of blood vesselblanching in the upper dermis.10,11 TCs havelong been used for their skin lightening propertiesand are often the most commonly used skin light-eners in Africa.12,13 TCs are believed to bleach theskin through inhibiting pro-opiomelanocortin(POMC), the precursor protein for a-melanocyte-stimulating hormone (a-MSH), which is producedin the intermediate lobe of the pituitary to stimulateepidermal melanin production.14
Mercurials
Mercury exists in three forms: organic, inorganic,and elemental.14 Mercury-containing creams andointments have been used for centuries to treat
infections (ie, syphilis),15 impetigo,16 phthiriasis(lice),17 and inflammatory skin diseases (ie, psori-asis),18 but more recently they have been usedas skin lighteners.8,14 Mercurials exert their skinlightening actions through inhibition of sulfhydrylenzymes or mercaptans,3 ultimately resulting insuppression of tyrosinase (the rate-limitingenzyme in the melanin pathway) and decreasedmelanogenesis.14
ADVERSE EFFECTS OF TOPICAL SKINLIGHTENING COMPOUNDSHydroquinone
Although hydroquinone is one of the most effectiveandpopular skin lighteningcompounds, it hasbeenshown to cause multiple cutaneous and systemicside effects.1 The most common acute complica-tion of hydroquinone use is irritant contact derma-titis (up to 70% of patients) (Fig. 1), followed byPIH, hypopigmentation, and allergic contactdermatitis.1,19,20 Chronic complications of hydro-quinone exposure include nail discoloration21e23
or “pseudo yellow-nail syndrome,”14 conjunctivalpigmentation,24 corneal melanosis and degener-ation,24e26 peripheral neuropathy,27 decreasedskin elasticity,14 impaired wound healing,14,28 andwound dehiscence,14,28 particularly after abdom-inal procedures such as caesarian section orhysterectomy. Another unique complication ofchronic hydroquinone use is trimethylaminuria or“fishodorsyndrome,”28,29characterizedbya rottenfish body odor caused by excretion of trimethyl-amine in the saliva, sweat, urine, and vagina.30 Anassociation between hydroquinone and squamouscell carcinoma has also been suggested, althoughall reported cases had a history of prior or concom-itant TC use.31,32 Further studies are needed to
Fig. 1. A Senegalese woman with a peculiar reddishhue that some bleaching creams cause.
Widespread Use of Toxic Skin Lightening Compounds 113
properly determine the risk of skin cancer in hydro-quinone users.
The most severe and widely recognized compli-cation of chronic hydroquinone use is exogenousochronosis,1,33 with at least 789 reported cases,756 of which occurred in Africa.34 Ochronosiscan exist in both endogenous and exogenousform, the former associated with alkaptonuria, anautosomal recessive disorder (1:25,000) charac-terized by the absence of homogentisic acidoxidase (HGOA),35 and the latter typically attrib-uted to hydroquinone-containing compounds.1,33
Exogenous ochronosis has also been associatedwith antimalarials,36e38; carbolic acid (phenol) legulcer compresses39,40; resorcinol41; mercury42;levodopa43; and picric acid.42 In the inheritedform, HGOA enzyme deficiency leads to homoge-ntisic acid accumulation, which polymerizes toform ochre-colored pigments that deposit in theskin, cartilage, and tendons.35,44 Alkaptonuria isclassically characterized by the triad of painlesscutaneous hyperpigmentation (ochronosis),arthritis, and homogentisic aciduria, in which urineturns black when left standing or on contact withair or an alkali.35,44 Thickening of the cartilage ofthe pinnae, calcification of the aortic valve andprostate gland, and dark cerumen are also charac-teristic.44 Although exogenous ochronosis is clini-cally and histologically similar to its endogenous
form, it is not inherited and no systemic symptomsare observed.
The term ochronosis (“yellow disease” inGreek) was coined by Virchow45 in 1866, whenhe described a patient whose cartilage ap-peared blue-black grossly, but was yellow-brown when viewed microscopically. In 1901,Pick46 reported the first exogenous form ofochronosis in a patient with prolonged exposureto phenols. In 1975, Findlay and colleagues33
described the first cases of hydroquinone-induced exogenous ochronosis in 35 SouthAfrican Bantu women that used high-concentration (3.5%e7%) hydroquinone forseveral years. In 1979, Dogliotte and Liebowitz47
classified exogenous ochronosis into threedifferent stages: (1) erythema and mild pigmen-tation, (2) hyperpigmentation, black colloid milia,and scanty atrophy, and (3) papulonodules withor without surrounding inflammation. The firstcase in the United States of exogenous ochro-nosis caused by hydroquinone use was reportedin 1983 by Cullison and colleagues,48 which wasfollowed with reports by Hoshaw andcolleagues,49 Connor and Braunstein,50 andLawrence and colleagues,51 all in patients usinglow-concentration (�3%) hydroquinone fora short duration (�1 year). Although varioustheories exist regarding the pathogenesis ofexogenous ochronosis, the most accepted isthat of Penneys’52 which attributes the conditionto hydroquinone’s inhibition of the enzymeHGOA, leading to the accumulation of homoge-ntisic acid, which then polymerizes to formochre pigments in the papillary dermis.
Exogenous ochronosis is characterized by gray-brown or blue-black macules coalescing intopatches, which are occasionally accompanied bypinpoint, dark brown, caviar-like papules.33,47,53
Exogenous ochronosis is typically symmetricallydistributed in photoexposed areas, particularlyover osseous surfaces in the infraorbital and zygo-matic regions,33 leading some to speculate thatultraviolet exposure might be a risk factor.54 Histo-logically, exogenous ochronosis is characterizedby normal epidermis, curved ochre-coloredbanana-shaped structures in the papillary dermis,dermal solar elastosis, and degeneration ofcollagen and elastic fibers.1,33,48 Occasionally,sarcoid-like granulomas with multinucleated giantcells are seen surrounding the ochronotic parti-cles.38,48,49,55 On dermoscopy, blue-gray amor-phous areas can be seen obliterating follicularopenings.53 The ochronotic pigment stainsblue-black with methylene blue and black withFontana stain; they do not stain with Prussianblue for iron.50,56
Ladizinski et al114
Several modalities have been experimentallyused to treat exogenous ochronosis, but resultshave not been reassuring.42 Some reports havenoted improvement with carbon dioxide laser,57
dermabrasion,57,58 Q-switched ruby laser,48
Q-switched alexandrite laser (755 nm),59 tetracy-cline 60 and retinoic acid,57,61 whereas cryotherapyand trichloroacetic acid have not shown effi-cacy.57 Occasionally, hydroquinone discontinua-tion leads to reversal of the hyperpigmentation,but this can take up to several years.33,48,49
Topical Corticosteroids
Although TCs are frequently used as skinlightening agents,12,13 they are associatedwith multiple dermatologic and systemicside effects.8,14,28,62,63 Common cutaneouscomplications associated with TC applicationinclude acne vulgaris,13,28,63 allergic contactdermatitis,13,64,65 skin atrophy,66e68 perioraldermatitis,68 hypertrichosis,28,63 rosacea,14,28
striae atrophica,13,28,63,67 and telangiectasias.63,66
The skin on the neck seems particularly prone toatrophy, sometimes producing a rippled, “pluckedchicken” appearance, otherwise known aspseudo-pseudoxanthoma elasticum.14 Chronicperiocular TC use can cause ophthalmologiccomplications, such as cataracts and glaucoma.14
TC users are also particularly prone to developinginfections such as cellulitis,14 dermatophyto-sis,13,28,63 erysipelas,14,28 folliculitis,14 andscabies.13,28 Dermatophyte infections are espe-cially common14 and include tinea incognito,14
widespread tinea corporis14 and tinea faciei,14
which can mimic roseacea69 or lupus erythemato-sus.70,71 Furthermore, chronic users are morelikely to develop viral warts,28 which tend toappear simultaneously on the neck and uppertrunk, a finding that Olumide and colleagues14
nicknamed the “pseudo Leser-Trelat sign.”TC use is also associated with various systemic
complications such as hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushingsyndrome,28,72,73 diabetes mellitus,63 and hyper-tension.74 The most worrisome of these complica-tions is HPA dysfunction causing adrenalinsufficiency,10,72,75,76 which can be life-threatening. Adrenal suppression has long beenregarded as a complication of high-dose TCs (ie,>50 g/wk of clobetasol propionate), but patientstaking low doses (ie, 7.5 g/wk) have also experi-enced adrenal suppression.77 In 2001, Perret andcolleagues78 assessed the functionality of theHPA axis among decade-long TC users in Senegaland reported significantly lower plasma cortisol
levels in response to cosyntropin stimulationcompared with controls.Another potential adverse effect from chronic
daily use of a potent TC is “steroid addictionsyndrome,” which is characterized by intenseburning and potentially permanent erythemadue to withdrawal vasodilatation.14 The irrevers-ible form of pronounced erythema, often referredto as homme rouge, occurs more commonly inmale users.14
Other less-common reactions reported with TCuse include avascular necrosis of the femoralhead79 and squamous cell carcinoma.31,32 Addi-tionally, chronic use of TCs may mask other path-ologic conditions, as was observed in a patientwith leprosy.80 The risk of these adverse reactionsis potentiated when high-potency formulations areused on sites with fragile, thin skin (ie, face, armpit,groin) for prolonged periods or under occlusion,which promotes penetration.10,14 Individualsparticularly at risk for developing adrenal suppres-sion include infants and patients with damagedskin barriers.10
Mercurials
Mercury-containing skin lightening agents ormercurials usually contain either mercury chlorideor calomel and ammoniated mercury chloride,which are inorganic salts.81 Mercury, as thimer-osal, is also commonly used in the manufacturingof mascara and other cosmetics.82 Acute orchronic exposure to topical mercury-containingcompounds can cause dermatologic, renal, andneurologic toxicity.16,81,82 Classically, mercurypoisoning was associated with felt hat manufac-turers, hence the name “mad hatters disease,” orin patients treated for cutaneous disorders suchas syphilis or impetigo. However, skin lighteningproducts have also emerged as a major cause ofmercury toxicity.8,14,83,84
Common cutaneous complications of mercuryuse include allergic contact dermatitis, flushing,erythroderma, purpura, gingivostomatitis, andnail discoloration.16,82,85,86 Chronic use of mercu-rial skin lighteners can cause a paradoxichyperpigmentation, which might be caused bydermal deposition of mercury-containing gran-ules.87 Mercury-induced neuropsychiatric toxicityincludes metallic taste, tremor, peripheral neurop-athy, erethrism, memory loss, anxiety, depression,and psychosis.16,84 Other complications includepositive antinuclear antibody titers88,89 and asuggested association with systemic lupus erythe-matosus (SLE),90 as metallic mercury exposurehas been shown to accelerate SLE develop-ment in lupus-prone mice.91 Maternal use of
Fig. 2. Skin lightening agents that are readily avail-able for sale in Ghana.
Widespread Use of Toxic Skin Lightening Compounds 115
mercury-containing soap during pregnancy hasresulted in prenatal and postnatal intoxication, asmercury can cross the placenta.16 In children, inor-ganic mercury exposure has also been associatedwith acrodynia.16
Nephrotoxicity is another potential complicationrelated to mercury use.83,88,92e96 In one report,50% of young African women in Kenya who usedmercury-containing skin lightening creams devel-oped glomerular lesions.92 The type of mercury-associated kidney injury depends on the form ofmercury and the rate of administration.83 Organicand metallic mercury are lipophilic and typicallycause neurotoxicity, whereas inorganic mercurytypically causes nephrotoxicity.97 Still, any formof mercury can cause tubular or glomerular renaldisease depending on the length of contact, withacute exposure usually causing tubular injury(acute tubular necrosis) and chronic exposureusually causing glomerular injury (membranousnephropathy, immune complexemediatedglomerulonephritis, minimal change dis-ease).83,88,92e96 Cole and colleagues15 showedthat the amount of mercury applied to the skin isproportional to the amount excreted by thekidneys. Still, mercury-induced membranousnephropathy typically resolves spontaneouslyafter exposure cessation.92
PSYCHOSOCIAL ASPECT
Although dermatologic disorders are not generallyconsidered to be life-threatening, suicide has beenreported in patients with “skin failure.”98e101 Psy-chodermatologic problems are more common inwomen, and facial symptomatology seems to bea particular risk factor for depression and suicidalideations.99 Disorders of pigmentation, such asmelasma, vitiligo, PIH, lentigo, and idiopathic gut-tate hypomelanosis, are prevalent and have beenshown to significantly impact health-relatedquality of life (HRQOL) in a deleterious man-ner.102e104 A recent United States study showedthat 80%of randomly selected patients at a privatedermatology clinic had pigmentation disordersthat significantly affected their quality of life.104
Approximately 47.3% of patients felt self-conscious about their skin, 32.7% felt unattractive,and 23.6% felt their disorder affected their day-to-day activities, although few patients sought orreceived treatment for these conditions.104 Treat-ment with skin lightening agents has been shownto improve these unfavorable psychosocial andHRQOL issues.103
The habitual use of skin lightening compoundshas long been commonplace in Africa, particularlyGhana31,105 (Fig. 2), Kenya,92 Nigeria,28,106
Senegal,13 and Zimbabwe,107 and in India,108 buthas recently become recognized in other parts ofthe world, including North America,48,49 SouthAmerica,53 Central America,109 Great Britain,83
Europe,110 Japan,111 Southeast Asia112 (Fig. 3),and the Middle East.113,114 For more than 50years, the mainstay of therapy for Black, White,Asian, Indian, and Hispanic individuals with hyper-pigmentation disorders has been hydroqui-none.115 Although traditionally regarded asa female practice, men in Africa commonly useskin lighteners,13 and recent articles suggest thatthey are becoming popular among men in India,116
North America,117 and Central America.109
Concerns regarding hydroquinone toxicity,particularly exogenous ochronosis and potentialcarcinogenicity, has led to rigid regulations inAfrica, an OTC ban in Europe, abolishment inJapan, and a proposed OTC ban in the UnitedStates. Despite these concerns, human exposureto hydroquinone is common, because it is typicallyfound in cosmetics,118 cigarette smoke,118 motorfuels and oils,118 photograph developer,118 andvarious foods, such as blueberries,118 cran-berries,118 pears,119 coffee,119 tea,119 and wheatproducts.119 Still, no reports of malignancy associ-ated with hydroquinone have been confirmed, andregulatory groups have determined that evidence
Fig. 3. Upscale pharmacy in Thailand.
Ladizinski et al116
is insufficient to classify hydroquinone as a carcin-ogen.1 In fact, several large studies have shownthat individuals with occupational exposure tohydroquinone have similar120 or decreased121,122
all-cause mortality and cancer rates comparedwith controls. Although excessive oral ingestionof photographic developer containing hydroqui-none has been associated with suicide,123 studiesinvestigating intentional ingestion of hydroquinonein large quantities have reported no significantabnormalities.25
Africa
Use of skin lightening products is popular inAfrica,80 with an estimated prevalence of 25% to96%.12,67 In Sub-Saharan Africa, a desire to havelighter skin has been reported as a major moti-vating factor for using these products, as whiteskin is still associated with social privileges incertain communities.28 Several prospectivestudies conducted in Dakar, Senegal showedthat skin lightening is most prevalent amongdark-skinned, illiterate, working, married womenbetween 30 to 44 years of age.12 TCs and hydro-quinone are the most frequently used lighteners,with joint hyperpigmentation, striae, and skinatrophy being the most commonly reportedcomplications.12,28
In a dermatologic clinic in Lagos, Nigeria, 92%of women and 5% of men reported using skinlighteners, and most were not aware that skinpigment served a protective function.28 A studyconducted at a maternity clinic in Dakar, Senegalby Mahe and colleagues124 showed that 68.7%of pregnant women used skin lighteners, specifi-cally hydroquinone and highly potent TCs,throughout their gestational period, some even re-porting initiating or increasing use as a result oftheir pregnancy. Regarding pregnancy outcomes,no significant difference was noted between skin
lighteners and controls, but users of highly potentTCs had lower plasma cortisol levels, smallerplacentas, and a higher rate of low birthweightinfants.124 Application of these agents is of partic-ular concern in Africa, where products are readilyavailable without prescription and are used forprolonged periods. Percutaneous absorption isalso enhanced in tropical climates because ofthe occlusive effect of heat and humidity.Exogenous ochronosis from hydroquinone use
is most commonly observed in Africans (>750 ofthe nearly 800 reported cases),34 but has alsobeen described in Americans,48,49,51 Mexicans,61
Brazilians,53 Spaniards,125 Asians,112 andArabs.126 The high prevalence in Africa may beconfounded by several factors, such as the wide-spread use of antimalarials in the area, which isalso known to cause exogenous ochronosis; thelack of biopsies performed; and the reliance onclinical diagnosis.8 Resorcinol is also often usedsimultaneously with hydroquinone to hasten light-ening, and the synergistic effect of these agentsmay contribute to the increased incidence ofexogenous ochronosis in Africa.127 Furthermore,in South Africa, most OTC hydroquinone productsare in the form of a penetrating enhancing vehicle(ie, hydroalcoholic lotion), which enhances cuta-neous absorption.128 After the study by Findlayand colleagues,33 in 1980 the upper limit of hydro-quinone in OTC skin lightening products in SouthAfrica was reduced from 8% to 2%,129 althoughno proper studies showed this concentration tobe safe.81
India
Studies assessing the prevalence of skin lighteningin India could not be found, although this practiceaccounts for approximately 61% (1000 crorerupees, $250 million) of the Indian dermatologicmarket.108 The desire for lighter skin in India likelyoriginated from the structure of Hinduism’s socialhierarchy, in which those belonging to highercastes typically had fairer complexions.116 Further-more, throughout its history, India has beeninvaded by lighter-skinned nations, such as GreatBritain, and therefore fairness, strength, andsupremacy have become interconnected.116
Today, lighter skin is associated with superiorstatus and beauty, as evidenced by newspapermatrimonial advertisements, in which fairnessis considered a favorable factor for engage-ment.108,116 Paradoxically, in a country fixated onattaining a fair complexion, depigmentation disor-ders, such as vitiligo, are socially stigmatized andhinder one’s possibility for marriage.108
Widespread Use of Toxic Skin Lightening Compounds 117
Although Indian women have used bleachingagents for decades, the skin lightening industryalso has began targeting men recently.116,130
Various television, newspaper, and Internet adver-tisements are attempting to convey the messagethat lighter skin makes men more attractive andsuccessful. For example, to promote its male-directed line of skin lighteners, Vaseline recentlyreleased a Facebook skin-whitening application,“Vaseline Men: Be Prepared,” inviting users to,“Transform your face on Facebook with Vaselinemen,” adding that their product “not only whitensyour skin but is also designed to reduce five typesof dark spots on your face.”130
Table 2Alternative skin lightening agents
Skin Lighteners Mechanism of Action
Aleosin Tyrosinase inhibition
Arbutin Tyrosinase inhibition
Azelaic acid Tyrosinase inhibition
Ascorbic acid Melanogenesis inhibition
Kojic acid Tyrosinase inhibition
Licorice extract Melanogenesis inhibition
Mequinol Tyrosinase inhibition
N-acetylglucosamine
Tyrosinase glycosylationinhibition
Retinoids Melanogenesis inhibition
Soy extract Melanosome transferinhibition
North America
No formal studies have assessed the prevalence ofskin lightening in North America. According to theUS Food and Drug Administration (FDA)Over-The-Counter Miscellaneous Panel, 2%hydroquinone has long been considered a safeconcentration.8 However, on August 29, 2006,the FDA proposed banning all OTC hydroquinoneskin lightening agents that were not approvedthrough the New Drug Application process.8,34,115
This motion was stimulated by the increasing inci-dence of hydroquinone-induced exogenousochronosis and other adverse drug reactions(most of which are reported in Africa), and severaldrug manufacturers’ disregard of the FDA’srequest for hydroquinone safety studies.8,34 Thepurpose of the proposal was to “establish thatOTCskin bleaching drugproducts are not generallyrecognized as safe and effective (GRASE),” ac-cording to the Kefauver Harris Amendment, whichwas passed in 1962 to ensure that drugs demon-strated efficacy in addition to safety, a requirementincluded in the original Food, Drug and CosmeticsAct of 1938.34,115 In March 2010, the FDA131
announced that the National Toxicology Programwould be conducting further studies on hydroqui-none’s potential for reproductive toxicity anddermal carcinogenicity in mice and rats.
Classically believed to only occur with useof high-concentration (�3.5%) hydroquinoneproducts used for prolonged periods (�1year),53,132 exogenous ochronosis has also beenreported with use of lower concentrations(�3%)48e51,53,61,125,133 and acute use (�1year).48e51,61 Of the 22 cases of exogenous ochro-nosis reported in the United States, 21 were asso-ciated with low-concentration hydroquinone(1%e2%), generally used for prolonged periods(�1 year).34 Thus, the average number of exoge-nous ochronosis cases reported in the UnitedStates is approximately one per year, or 1 in 10
million tubes sold, leading some to disagree withthe FDA, believing that hydroquinone’s benefitsoutweigh its risks.34
In 1973, mercury-containing cosmetics werebanned in the United States because of safetyconcerns but, despite this apparent prohibition,unregulated mercurials are still readily attainablewithout a prescription. In 1996, mercury poisoningassociated with a skin lightening product, Cremede BellezadManning, which was produced inMexico and illegally imported into the UnitedStates, was reported in more than 400 Mexican-American women in Arizona, California, NewMexico, and Texas.134,135 Recently, toxicity asso-ciated with mercury-containing soap has beenreported,136 and an investigation of 50 skin light-ening creams, most purchased OTC in Chicagostores and some online, detected unlawfulamounts of mercury in 6 products.137
ALTERNATIVES TO TRADITIONAL SKINLIGHTENING COMPOUNDS
The gold standard dermatologic agent for skinlightening has classically been hydroquinone, untilregulatory agencies in Africa, Asia, Europe, andthe United States questioned its safety profile.This scrutiny encouraged research into alternativeagents to reduce skin pigmentation, such as aleo-sin, arbutin, azelaic acid, ascorbic acid, kojic acid,licorice extract, mequinol, N-acetyl glucosamine,soy proteins, and retinoids138 (Table 2). The threeprimary prescription alternatives to hydroquinoneare mequinol (4-hydroxyanisole), often in combi-nation with 0.01% tretinoin and vitamin C (ascor-bic acid)138; azelaic acid,138,139 which is derivedfrom Pityrosporum ovale cultures; and retinoids,in the form of adapalene, tazarotene, and
Ladizinski et al118
tretinoin.138,140 The most effective OTC alterna-tives to hydroquinone are arbutin,141 extractedfrom the leaves of the bear-berry plant; itssynthetic and more efficacious form, deoxyarbu-tin142; and kojic acid,143 which is obtained fromAspergillus and Penicillium cultures. Other less-effective, but safer OTC alternative agents includelicorice extract (liquiritin)144; soybean extract(soybean trypsin inhibitor [STI])145; N-acetylglucosamine146; aleosin,147 derived from the aloevera plant and often combined with arbutin or de-oxyarbutin to enhance effectiveness138; and as-corbic acid,148 which is typically ineffectiveunless used in combination with licorice extract,retinoids, or STI.138 Given the questionable toxicityof currently popular skin lighteners on the market,further investigations into effective alternativeagents with enhanced safety profiles arenecessary.Due to potential for various cutaneous and
systemic complications associated with mono-therapeutic skin lightening agents, combinationcompounds have been manufactured to reducetoxicity and improve effectiveness. In 2002,a triple-combination cream composed of 4%hydroquinone, 0.01% fluocinolone acetonide(class VI low-potency TC), and 0.05% tretinoin orretinoic acid (Tri-Luma) was FDA-approved forthe treatment of melasma. Once-daily applicationof this triple-combination therapy (TCT) wasshown to be more effective for treating melasmathan monotherapies (4% hydroquinone appliedtwice daily)149,150 and dual therapies (hydroqui-none1 retinoic acid; hydroquinone1 fluocinoloneacetonide; or fluocinolone acetonide 1 retinoicacid).104 Compared with hydroquinone alone,TCT was associated with superior patient satisfac-tion,149 enhanced self-perception,151 overallquality of life improvement,152 and improvedcost-effectiveness,126,150 as well as a comparablesafety profile.104,149,150,152
Furthermore, TC-induced skin atrophy has beenminimal in patients using combination creams,possibly because of tretinoin, which seems to actas a protective factor by promoting dermalcollagen synthesis and epidermal growth withoutlessening the anti-inflammatory effect.153 Inci-dence of adverse events have varied amongstudies, with similar104,150 and worse149 safetyprofiles reported with TCT, although all complica-tions have been mild, with no reports of severeside effects. The most commonly reportedadverse effects associated with TCT are erythema,burning, and desquamation, with few reports ofminor atrophy and no reports of exogenous ochro-nosis.104,149,150,154 Two cases of skin atrophyrelated to TCT use have been reported, although
reactions were mild and did not lead to treatmentdiscontinuation.154 Therefore, TCT seems to beeffective and exhibits a safe profile with low poten-tial for adverse events.
SUMMARY
Given the widespread use of topical skin lighteningcompounds, practicing dermatologists must beaware of their current clinical indications andpotential adverse effects. Dermatologists shouldalso be able to differentiate melasma fromhydroquinone-induced exogenous ochronosis,because these conditions are often confused.Prescriptions for skin lightening products shouldbe precise in terms of concentration, amount toapply, and duration of treatment. Furthermore,patients should be provided with informationregarding potential adverse effects, such as exog-enous ochronosis or skin atrophy, and potentiationof these toxicities if multiple lightening agents areused simultaneously. If any of the aforementionedsevere effects occur, the offending agent shouldbe discontinued and, if treatment is still necessary,an alternative prescribed, such as mequinol orazelaic acid. Further studies investigating theprevalence of skin lightener use, motivatingfactors, and complications are warranted in theUnited States, India, and other countries whereskin bleaching is practiced.
ACKNOWLEDGMENTS
The authors kindly acknowledge Dr ScottNorton for the generous contribution of hisphotographs.
REFERENCES
1. Nordlund JJ, Grimes PE, Ortonne JP. The safety of
hydroquinone. J Eur Acad Dermatol Venereol 2006;
20(7):781e7.
2. Jimbow K, Obata H, Pathak MA, et al. Mechanism
of depigmentation by hydroquinone. J Invest Der-
matol 1974;62(4):436e49.
3. Denton CR, Lerner AB, Fitzpatrick TB. Inhibition of
melanin formation by chemical agents. J Invest
Dermatol 1952;18(2):119e35.
4. Barber ED, Hill T, Schum DB. The percutaneous
absorption of hydroquinone (HQ) through rat and
human skin in vitro. Toxicol Lett 1995;80(1e3):
167e72.
5. Oettel H. Hydroquinone poisoning. Arch Exp Pathol
Pharmacol 1956;183:319e62.
6. Martin GJ, Ansbacher S. Confirmatory evidence of
the chromotrichal activity of p-aminobenzoic acid.
J Biol Chem 1941;13:441.
Widespread Use of Toxic Skin Lightening Compounds 119
7. Denton CR. Skin protective agents. Med Bull (Ann
Arbor) 1952;18(5):143e52.
8. Dadzie OE, Petit A. Skin bleaching: highlighting